Database

Startups

eXCELL Biotherapeutics Inc.

eXCELL Biotherapeutics Inc.

Selected as a startup company by FINDIT Matchmaking in the past two years
Update:2026/01/07
Industries
Main Industry
Health Care
Main Product/Service
eXCELL is an immunotherapy company that uses the body built-in immune rejection responses to non-self cells to combat the difficult-to-treat cancers by utilizing xenogeneic cells that could promote cancer immunity cycle due to the similarities between xen
Founded Year
2019
Unified Business No.
82820364
Status
Active
Number of Employees
6
Total Paid-in Capital
47,533,330 (NT$)
Location of Company
Taiwan , Taichung City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you. Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
About the Company
To discover, develop, and diver transformative xenogeneic cellular medicines to cancer patients and improve their outcomes. eXCELL is a company dedicated to developing revolutionary therapies to meliorate people’s lives.



More ↓

Similar Companies

HONYA MEDICAL CO., LTD.

1. Cell Therapy
2. Clinical trial
3. MCRcI®
4. MiSaver®

TRUST BIO-SONICS INC.

1. Ultrasound Imaging Agents
2. Ultrasound-Mediated Targeted Delivery

TAIWAN BIO THERAPEUTICS INC.

Leveraging the FAST CGT platform to enhance the specificity, persistence, and stability of regulatory T cells, improving their ability to restore immune tolerance and suppress inflammation as a targeted alternative to non-selective, high-risk immunosuppre